Obviousness

Obviousness Analysis under 35 U.S.C. § 103 for US Patent 12527771

A person having ordinary skill in the art (PHOSITA) in the field of pharmaceutical synthesis, particularly process chemistry for antiviral compounds like maribavir, would possess knowledge of standard synthetic methodologies, reaction optimization techniques, and purification strategies. This includes familiarity with common solvents, catalysts, protecting groups, and methods for improving yield, purity, and scalability of chemical processes.

The primary prior art reference for this analysis is U.S. Pat. No. 6,617,315 (hereafter, the '315 patent), which is explicitly identified in the present patent as disclosing aspects of maribavir synthesis. Other references, U.S. Pat. Nos. 6,482,939, 8,546,344, and 11,130,777, relate to polymorphic forms of maribavir, which are downstream product characteristics rather than the synthetic methods claimed in the independent claims.

The present patent (US12527771) generally frames its invention as providing an "improved synthesis of maribavir" with "increased overall yield" and "reduced and/or low levels of impurities," particularly when scaling up the synthesis. This objective of improving an existing synthetic process is a routine motivation for a PHOSITA in process chemistry.

Independent Claim 1: Method for Preparing Compound 2

Claim 1 describes a method for preparing a compound of Formula 2 (an intermediate for maribavir) by combining a compound of Formula 5 and a compound of Formula 6 in a solvent amount between 1.0 L/kg and 10.0 L/kg of Compound 5. The mixture is heated to a temperature (T7) between approximately 90° C. and 110° C. and maintained for 12 to 20 hours. R1 and R2 groups are broadly defined.

• Prior Art Teaching: The '315 patent explicitly "discloses an alternative route: synthesis of 2-(alkylamino)-1H-benzimidazoles," which are generic to Compound 2a and thus encompass Compound 2 as claimed in US12527771. This demonstrates that the fundamental chemical transformation to produce Compound 2 was known in the art prior to the present invention.
• Motivation to Combine/Modify: A PHOSITA, faced with the known synthesis of 2-(alkylamino)-1H-benzimidazoles from the '315 patent, would be routinely motivated to optimize the reaction conditions to achieve a higher yield, improved purity, or greater efficiency, especially when considering large-scale pharmaceutical manufacturing. The present patent itself states, "the present invention encompasses the recognition that the synthesis of maribavir can be modified to increase the overall yield." Such optimization would naturally involve adjusting parameters like solvent volume, reaction temperature, and reaction time.
• Predictability/Routine Nature of Modification: The specific ranges claimed for the solvent amount (1.0 L/kg to 10.0 L/kg), temperature (90° C. to 110° C.), and reaction time (12 to 20 hours) fall within the bounds of routine experimentation typically performed by a PHOSITA to optimize a known chemical reaction. Exploring these ranges to find optimal conditions for yield and purity is a standard practice in process development. For example, the patent notes that "a lower volume of reaction solvent e.g., 1,4-dioxane" can be used, implying optimization of solvent usage.

Independent Claim 8: Method for Preparing Compound 3

Claim 8 details a method for preparing a compound of Formula 3 (another maribavir intermediate) by combining the compound of Formula 2 (as defined in Claim 1) and a compound of Formula 8 in a solvent amount between 1.0 L/kg and 10.0 L/kg of Compound 2. The reaction mixture is heated to a temperature (T1) between approximately 90° C. and 110° C. and held for 12 to 20 hours to yield the compound of Formula 3. R1 and R2 are defined as in Claim 1, PG1 is a suitable oxygen protecting group, and X represents a salt of compound 3a.

• Prior Art Teaching: The '315 patent teaches the "coupling 2-(alkylamino)-1H-benzimidazoles [Compound 2] with 1,2,3,5-tri-O-acetyl-ribofuranose [Compound 8]" to produce an acetyl-protected intermediate, which is generic to Compound 3a and thus encompasses Compound 3 (when PG1 is acetyl). The '315 patent therefore describes the core chemical transformation.
• Motivation to Combine/Modify: A PHOSITA would be motivated to optimize the coupling reaction conditions described in the '315 patent to improve the yield and purity of the intermediate Compound 3, which is critical for the overall efficiency of maribavir synthesis. The present patent explicitly recognizes that "certain reagents (and amounts thereof) and/or reaction conditions may provide improved quality compound 3, or a salt thereof (e.g., with higher purity and/or minimal byproducts), and/or improve the yield and/or purity of compound 3, or a salt thereof." Additionally, the incorporation of crystallization, including salt formation, to purify intermediates is a well-established technique in pharmaceutical chemistry to achieve desired purity profiles and facilitate isolation.
• Predictability/Routine Nature of Modification: Similar to Claim 1, the claimed ranges for solvent amount (1.0 L/kg to 10.0 L/kg), temperature (90° C. to 110° C.), and reaction time (12 to 20 hours) are parameters commonly optimized through routine experimentation by a PHOSITA. The use of "a salt" (X) for compound 3a is also a routine practice for improving crystallization and purification of organic compounds. The patent states that "incorporation of a crystallization (e.g., comprising salt formation) into Step 2 may improve the yield and/or reduce the formation of byproducts," confirming that this is an optimization of a known synthetic route.

Independent Claim 12: Method for Preparing Maribavir

Claim 12 describes a method for preparing maribavir, or a pharmaceutically acceptable salt thereof, by combining the compound of Formula 3 (as defined in Claim 8) and a compound of Formula 4 in a solvent amount between 5.0 L/kg and 10.0 L/kg of Compound 3. The mixture is heated to a temperature (T4) between approximately 50° C. and 70° C. and maintained for 1 to 5 hours to produce maribavir. PG1 is a suitable oxygen protecting group.

• Prior Art Teaching: The '315 patent discloses the "deprotection of 2-(alkylamino)-1-(2,3,5-tri-O-acetyl-beta-L-ribofuranosyl-1H-benzimidazoles" to yield maribavir. While the present patent states that the '315 patent "does not exemplify deacetylation... to afford maribavir," the general concept of deprotection of the protected intermediate (Compound 3) to obtain maribavir is clearly taught. Compound 4 would represent the deprotecting agent used in this step.
• Motivation to Combine/Modify: A PHOSITA would be motivated to complete the synthesis of maribavir from the known protected intermediate (Compound 3) by performing the deprotection step, as described generally in the '315 patent. Optimization of this final step is essential to ensure high yield and purity of the active pharmaceutical ingredient.
• Predictability/Routine Nature of Modification: The selection of suitable deprotecting agents (represented by Compound 4) and the optimization of reaction conditions (solvent amount between 5.0 L/kg and 10.0 L/kg, temperature between 50° C. and 70° C., and reaction time between 1 and 5 hours) for deprotection of an acetyl-protected ribofuranosyl derivative are routine tasks for a PHOSITA. These parameters are commonly varied in process development to achieve efficient and high-quality product formation.

Conclusion on Obviousness

The independent claims of US12527771, directed to methods for preparing maribavir and its intermediates, would likely be considered obvious over U.S. Pat. No. 6,617,315. The '315 patent teaches the core synthetic pathway, including the formation of Compound 2, Compound 3, and the deprotection to maribavir. A PHOSITA, motivated to develop a more efficient, higher-yielding, and purer manufacturing process for a known pharmaceutical compound, would routinely explore and optimize the reaction parameters (e.g., solvent volumes, temperatures, reaction times, and purification methods like crystallization and salt formation) that are claimed in US12527771. The specific ranges and conditions claimed, while potentially representing an optimized process, do not appear to present unexpected results that would overcome the strong prima facie case of obviousness arising from the known synthetic route and the routine nature of process optimization.